Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › ELVN

SILVERARC CAPITAL MANAGEMENT, LLC position in ELVN

ENLIVEN THERAPEUTICS INC · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 121,452 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$5.6M, representing 0.71% of its reported portfolio and ranking #37 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ELVN holdings in 4 of the last 6 reported quarters, going back to Q2 2025.

Latest position (Q3 2026)121.45K sh
Reported value held$5.57M
Portfolio Weight0.71%
First reportedQ2 2025
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's ELVN position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in ELVN in Q2 2025 at 10,000 shares (US$201K). The position peaked in Q2 2026 at 489,382 shares, worth US$24.8M. Across 4 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 121,452 shares valued at US$5.6M — a reduction of -367,930 shares quarter over quarter.. Notable position changes include a 75% trim in Q3 2026 (shares rose 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 10.00K $200.60K New
Q3 2025 10.68K $218.52K Add
Q2 2026 489.38K $24.84M New
Q3 2026 121.45K $5.57M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ELVN and 13F data

ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 68 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$326.4M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ELVN

All ELVN fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held ELVN?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ELVN holdings in 4 of the last 6 reported quarters, going back to Q2 2025.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in ELVN?

As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 121.45K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $5.57M, representing 0.71% of its reported portfolio and ranking #37.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling ELVN?

In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC reduced its position in ELVN. The position peaked in Q2 2026 at 489.38K shares.

Which other funds hold ELVN?

Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 68 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.